StreetInsider.com News Articles

Tango Therapeutics to present cancer drug combo data at ESMO 2026

Fri, 16 Oct 2026 07:01:22 -0400

Tango Therapeutics, Inc. (NASDAQ: TNGX) will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23–27, 2026, in Madrid, Spain.

The study examines the drug combination in patients with MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The poster presentation, assigned abstract number 3149P, is scheduled for Sunday, October 25, 2026, between 12:00 and 12:45 pm CEST. Alexander I. Spira, MD, PhD, FACP, of NEXT Oncology in Fairfax, Virginia, will serve as presenter.

Abstracts will

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Fri, 16 Oct 2026 07:00:00 -0400

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET

BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Fri, 16 Oct 2026 07:00:00 -0400

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET

William Blair Starts Tango Therapeutics Inc. (TNGX) at Outperform

Fri, 16 Oct 2026 05:25:14 -0400

(Updated - October 16, 2026 5:25 AM EDT)

William Blair analyst Alethia Young initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Outperform rating.

The analyst comments "We are initiating coverage of Tango Therapeutics with an Outperform Rating and a DCF valuation of $42 per share. Tango is a precision oncology company with an in-house CRISPR-based discovery engine that identifies synthetic lethal targets created when cancers lose tumor suppressor genes. This engine generated vopimetostat (vopi), a PRMT5 inhibitor for MTAP-deleted cancers, a large market with 60,000 new patients per year."

For an analyst ratings summary and ratings history on Tango Therapeutics Inc.

William Blair Starts Tango Therapeutics Inc. (TNGX) at Outperform

Fri, 16 Oct 2026 05:25:14 -0400

(Updated - October 16, 2026 5:25 AM EDT)

William Blair analyst Alethia Young initiates coverage on Tango Therapeutics Inc. (NASDAQ: TNGX) with a Outperform rating.

For an analyst ratings summary and ratings history on Tango Therapeutics Inc.

JPMorgan Adds Positive Catalyst Watch on Tango Therapeutics Inc. (TNGX)

Tue, 13 Oct 2026 07:58:07 -0400

JPMorgan analyst Brian Cheng reiterated an Overweight rating and $48.00 price target on Tango Therapeutics Inc. (NASDAQ: TNGX).

The analyst comments "We hosted TNGX’s CEO, President of R&D, and CFO on our Biotech Call Series last week (replay here) followed by an investor huddle. Coming out of our Boston meeting with mgmt (note), mgmt continued to sound very confident in the vopi+darax combo heading into ESMO (#3149P; online poster release Oct 23, 2am ET / 8am CEST; see our preview). As a result, we are placing TNGX on Positive Catalyst Watch. See our key takeaways below: • Messaging Continued to Appear

JPMorgan Adds Positive Catalyst Watch on Tango Therapeutics Inc. (TNGX)

Tue, 13 Oct 2026 07:58:07 -0400

JPMorgan analyst Brian Cheng reiterated an Overweight rating and $48.00 price target on Tango Therapeutics Inc. (NASDAQ: TNGX).

Form 4 Tango Therapeutics, Inc. For: Oct 01 Filed by: Crystal Adam

Mon, 05 Oct 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20261005/27150172.html

Form 4 Tango Therapeutics, Inc. For: Sep 22 Filed by: Newcomb Jessica

Thu, 24 Sep 2026 19:42:00 -0400

si-local-file:///var/storage/secattach/20260924/27103188.html

Form 144 Tango Therapeutics, Inc. Filed by: Newcomb Jessica

Tue, 22 Sep 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260922/27091213.html

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:05:00 -0400

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:05:00 -0400

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics
Tango

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

About Tango Therapeutics
Tango

Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:28 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $68.00 (from $66.00) while maintaining a Buy rating.

The analyst commented: "For 2Q26, Tango recorded net earnings of $0.37 per share vs. our previously estimated net earnings of $0.30 per share. R&D and SG&A expenses were $37.2M and $22.6M, respectively vs. our estimates of $34.9M and $16M. We now project a full-year 2026 net loss of $1.34 per share vs. our prior net loss estimate of $1.14 per share. Tango ended 2Q26 with ~$1B in cash, cash equivalents,

Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:28 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $68.00 (from $66.00) while maintaining a Buy rating.

Tango Therapeutics Inc. (TNGX) Reiterated at Buy by Stifel: 3 Catalysts by YE26

Mon, 17 Aug 2026 07:49:58 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $40.00 price target on Tango Therapeutics Inc. (NASDAQ: TNGX).

The analyst commented, "Expectations for the vopimetostat+RAS(ON) inhibitor combination ESMO 2026 poster? Expect longer follow-up from the June disclosure, with some additional patients. Management cautioned against expecting too many newly enrolled patients to be reflected in ESMO efficacy data - time window is pretty narrow to enroll patients who would have the 14+ weeks of required follow-up to be efficacy evaluable by the ESMO data cut-off. Investors expect around a doubling of the efficacy evaluable vopi+darax patients in PDAC (DL1+DL2) in the ESMO

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932148.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932148.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930817.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930817.html

Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC

Fri, 14 Aug 2026 14:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26928837.html

Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC

Fri, 14 Aug 2026 14:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26928837.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26927053.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26927053.html